Ma F, Wu J, Fu L, Li A, Lan B, Chen K
J Natl Cancer Cent. 2024; 1(3):97-100.
PMID: 39036376
PMC: 11256670.
DOI: 10.1016/j.jncc.2021.07.003.
Jackson L, Weedon M, Green H, Mallabar-Rimmer B, Harrison J, Wood A
EClinicalMedicine. 2023; 64:102159.
PMID: 37936660
PMC: 10626157.
DOI: 10.1016/j.eclinm.2023.102159.
Gebhart P, Tan Y, Muhr D, Stein C, Singer C
Breast Care (Basel). 2023; 18(5):412-416.
PMID: 37901051
PMC: 10601672.
DOI: 10.1159/000531612.
Choi J, Ha T, Choi H, Lee H, Shin H, Chung W
Cancer Epidemiol Biomarkers Prev. 2023; 32(9):1182-1189.
PMID: 37310812
PMC: 10472098.
DOI: 10.1158/1055-9965.EPI-23-0064.
Davey M, Kerin M
Br J Surg. 2023; 110(7):743-745.
PMID: 36753055
PMC: 10364497.
DOI: 10.1093/bjs/znad017.
Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review.
Wei X, Oxley S, Sideris M, Kalra A, Sun L, Yang L
Cancers (Basel). 2022; 14(24).
PMID: 36551605
PMC: 9776851.
DOI: 10.3390/cancers14246117.
Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B, Helms M, Besch L, Kalmbach N, Stegen S, Blohmer J
Arch Gynecol Obstet. 2022; 307(5):1585-1592.
PMID: 36307613
PMC: 10110675.
DOI: 10.1007/s00404-022-06819-3.
Low-level constitutional mosaicism of BRCA1 in two women with young onset ovarian cancer.
Speight B, Colvin E, Epurescu E, Drummond J, Verhoef S, Pereira M
Hered Cancer Clin Pract. 2022; 20(1):32.
PMID: 36068545
PMC: 9446595.
DOI: 10.1186/s13053-022-00237-x.
Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population.
Shen L, Zhang S, Wang K, Wang X
Front Oncol. 2021; 11:740227.
PMID: 34926254
PMC: 8671637.
DOI: 10.3389/fonc.2021.740227.
Clinical implementation of an oncology-specific family health history risk assessment tool.
Fung S, Wu R, Myers R, Goh J, Ginsburg G, Matchar D
Hered Cancer Clin Pract. 2021; 19(1):20.
PMID: 33743786
PMC: 7981979.
DOI: 10.1186/s13053-021-00177-y.
The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer.
Basu N, Hodson J, Chatterjee S, Gandhi A, Wisely J, Harvey J
Sci Rep. 2021; 11(1):2847.
PMID: 33531640
PMC: 7854742.
DOI: 10.1038/s41598-021-82654-x.
Preferences for breast cancer prevention among women with a or mutation.
Mansfield C, Metcalfe K, Snyder C, Lindeman G, Posner J, Friedman S
Hered Cancer Clin Pract. 2020; 18:20.
PMID: 33014209
PMC: 7526374.
DOI: 10.1186/s13053-020-00152-z.
Evaluation of family health history collection methods impact on data and risk assessment outcomes.
Wu R, Sultana R, Bylstra Y, Jamuar S, Davila S, Lim W
Prev Med Rep. 2020; 18:101072.
PMID: 32181122
PMC: 7066218.
DOI: 10.1016/j.pmedr.2020.101072.
SEOM clinical guidelines in hereditary breast and ovarian cancer (2019).
Gonzalez-Santiago S, Ramon Y Cajal T, Aguirre E, Ales-Martinez J, Andres R, Balmana J
Clin Transl Oncol. 2020; 22(2):193-200.
PMID: 31889241
DOI: 10.1007/s12094-019-02262-0.
The impact of alcohol consumption and physical activity on breast cancer: The role of breast cancer risk.
Rainey L, Eriksson M, Trinh T, Czene K, Broeders M, van der Waal D
Int J Cancer. 2019; 147(4):931-939.
PMID: 31863475
PMC: 7383781.
DOI: 10.1002/ijc.32846.
Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease.
Puzhko S, Gagnon J, Simard J, Knoppers B, Siedlikowski S, Bartlett G
Public Health Rev. 2019; 40:2.
PMID: 30858992
PMC: 6394012.
DOI: 10.1186/s40985-019-0111-5.
Differences between screen-detected and interval breast cancers among BRCA mutation carriers.
Pilewskie M, Zabor E, Gilbert E, Stempel M, Petruolo O, Mangino D
Breast Cancer Res Treat. 2019; 175(1):141-148.
PMID: 30673971
PMC: 6494691.
DOI: 10.1007/s10549-018-05123-6.
GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in and Pathogenic Variant Carriers.
Lesueur F, Mebirouk N, Jiao Y, Barjhoux L, Belotti M, Laurent M
Front Oncol. 2018; 8:490.
PMID: 30430080
PMC: 6220051.
DOI: 10.3389/fonc.2018.00490.
Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool.
Tea M, Tan Y, Staudigl C, Eibl B, Renz R, Asseryanis E
PLoS One. 2018; 13(7):e0200559.
PMID: 30001421
PMC: 6042777.
DOI: 10.1371/journal.pone.0200559.
Trends in breast reconstruction practices in a specialized breast tertiary referral centre.
OHalloran N, Lowery A, Kalinina O, Sweeney K, Malone C, McLoughlin R
BJS Open. 2018; 1(5):148-157.
PMID: 29951617
PMC: 5989961.
DOI: 10.1002/bjs5.23.
